-
NewLink Genetics' Potential Catalysts Not Enough To Justify A Bullish Stance, Baird Says In Downgrade
Monday, April 9, 2018 - 2:24pm | 355Read More...NewLink Genetics Corp (NASDAQ: NLNK) said Friday it will review the clinical programs for its indoximod therapy after rival Incyte Corporation (NASDAQ: INCY) announced disappointing results from a study of the similar therapy epacadostat. The Analyst Baird Equity Research's Michael Ulz...
-
Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial
Monday, April 9, 2018 - 10:29am | 422Read More...NewLink Genetics Corp (NASDAQ: NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK) and Incyte Corporation (NASDAQ: INCY) said their clinical trial of the similar drug epacadostat...
-
Analyst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside
Monday, September 11, 2017 - 3:15pm | 644Read More...Investors and analysts don’t seem to be in lockstep when it comes to NewLink Genetics Corp (NASDAQ: NLNK)’s potential. On Monday, the biotech firm secured Buy reiterations from Stifel Nicolaus and Cantor Fitzgerald, and last week, it earned upgrades to Buy from Jefferies and Baird...
